文献速递头颈部肿瘤放疗

头颈部鳞癌放化疗前后及随访期淋巴细胞亚群组成:未复发与复发患者比较

Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
PubMed 文献 · Radiat Oncol · 2021-07-31

本研究为德国癌症联盟放射肿瘤组多中心前瞻性研究,比较23例未局部区域复发与9例局部区域复发头颈部鳞癌患者在原发放化疗前、中及随访期外周血主要淋巴细胞亚群的组成与动力学,并以22名年龄相关健康志愿者为对照。结果显示未复发患者CD19+ B细胞在治疗前即低于健康人,CD3+及CD4+ T细胞持续下降而CD8+及NKT逐渐升高,Tregs放化疗后先降后升;复发患者CD4+ T细胞持续低平,活化NK细胞亚群在未复发者中持续升高至6个月,而复发者直至复发时仍稳定低平。结论提示监测淋巴细胞亚群尤其活化NK细胞动力学可能有助于提示早期局部区域复发,但需更大样本研究。

要点

  • 未复发患者CD19+ B细胞治疗前低于健康人,3个月进一步下降,6个月恢复初始水平。
  • 未复发者CD3+和CD4+ T细胞持续下降,CD8+和NKT逐渐升高,Tregs先降后升。
  • 复发患者CD4+ T细胞持续低平,活化NK细胞亚群至复发时仍稳定低平。

核心结论

  • 监测放化疗前后淋巴细胞亚群尤其活化NK细胞动力学可能提示头颈部鳞癌早期局部区域复发。
  • 研究需要更大样本队列验证。

研究设计与样本

  • 德国癌症联盟放射肿瘤组多中心前瞻性研究,纳入23例未局部区域复发和9例局部区域复发头颈部鳞癌患者,22名年龄相关健康志愿者为对照。
  • EDTA血在多时间点采集:未复发患者于治疗前(t0)、20-30 Gy后(t1)、放化疗后3个月(t2)和6个月(t3);复发患者于t0、t1、t2及复发时(t5)。
  • 采用多参数流式细胞术表型分析主要淋巴细胞亚群。

主要发现

  • 未复发患者CD19+ B细胞比例在t0显著低于健康人,至t2进一步下降,t3恢复初始水平。
  • 未复发患者CD3+ T和CD3+/CD4+ T辅助细胞在t0至t3持续下降,而CD8+细胞毒性T细胞和CD3+/CD56+ NKT细胞同期逐渐升高。
  • 未复发患者CD4+/CD25+/FoxP3+ Tregs放化疗后立即下降,但在t2和t3升高超过初始水平。
  • 复发患者B细胞、T细胞和Tregs在t0至t5呈相似趋势,但CD4+ T辅助细胞在t0至t5持续低平。
  • 未复发患者NKT/NK亚群(CD56+/CD69+、CD3-/CD56+、CD3-/CD94+、CD3-/NKG2D+、CD3-/NKp30+、CD3-/NKp46+)在t0至t3持续升高至6个月,复发患者这些亚群至t5稳定低平。

临床怎么用

  • 放化疗前及随访期可考虑监测外周血淋巴细胞亚群,尤其活化NK细胞亚群动态。
  • CD4+ T细胞持续低平及活化NK细胞不升高可能提示局部区域复发风险。
  • 目前证据尚不足以据此改变临床决策,需更大样本验证。

局限性

  • 复发患者样本量仅9例,未复发患者23例,样本量较小。
  • 作者指出需要更大患者队列研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiochemotherapy (RCT) has been shown to induce changes in immune cell homeostasis which might affect antitumor immune responses. In the present study, we aimed to compare the composition and kinetics of major lymphocyte subsets in the periphery of patients with non-locoregional recurrent (n = 23) and locoregional recurrent (n = 9) squamous cell carcinoma of the head and neck (SCCHN) upon primary RCT. METHODS: EDTA-blood of non-locoregional recurrent SCCHN patients was collected before (t0), after application of 20-30 Gy (t1), in the follow-up period 3 (t2) and 6 months (t3) after RCT. In patients with locoregional recurrence blood samples were taken at t0, t1, t2 and at the time of recurrence (t5). EDTA-blood of age-related, healthy volunteers (n = 22) served as a control (Ctrl). Major lymphocyte subpopulations were phenotyped by multiparameter flow cytometry. RESULTS: Patients with non-recurrent SCCHN had significantly lower proportions of CD19+ B cells compared to healthy individuals before start of any therapy (t0) that dropped further until 3 months after RCT (t2), but reached initial levels 6 months after RCT (t3). The proportion of CD3+ T and CD3+/CD4+ T helper cells continuously decreased between t0 and t3, whereas that of CD8+ cytotoxic T cells and CD3+/CD56+ NK-like T cells (NKT) gradually increased in the same period of time in non-recurrent patients. The percentage of CD4+/CD25+/FoxP3+ regulatory T cells (Tregs) decreased directly after RCT, but increased above initial levels in the follow-up period 3 (t2) and 6 (t3) months after RCT. Patients with locoregional recurrence showed similar trends with respect to B, T cells and Tregs between t0 and t5. CD4+ T helper cells remained stably low between t0 and t5 in patients with locoregional recurrence compared to Ctrl. NKT/NK cell subsets (CD56+/CD69+, CD3-/CD56+, CD3-/CD94+, CD3-/NKG2D+, CD3-/NKp30+, CD3-/NKp46+) increased continuously up to 6 months after RCT (t0-t3) in patients without locoregional recurrence, whereas in patients with locoregional recurrence, these subsets remained stably low until time of recurrence (t5). CONCLUSION: Monitoring the kinetics of lymphocyte subpopulations especially activatory NK cells before and after RCT might provide a clue with respect to the development of an early locoregional recurrence in patients with SCCHN. However, studies with larger patient cohorts are needed. TRIAL REGISTRATION: Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio), NCT02059668. Registered on 11 February 2014, https://clinicaltrials.gov/ct2/show/NCT02059668 .

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Niu M, Combs SE, Linge A, et al. Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiat Oncol. 2021. PMID: 34332614. doi:10.1186/s13014-021-01868-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。